IPOs: NeuroSigma withdraws, NovoCure and SynCardia to go out; Ubl to leave AdvaMed;

@FierceMedDev: ICYMI: In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko. More | Follow @FierceMedDev

@StacyALawrence: JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention. Story | Follow @StacyALawrence

@VarunSaxena2: From @FierceMedDev's special report on recalls: Patients struggle to safely use HeartWare's blood pump. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Shire chalks up victory in Vyvanse patent battle. Article | Follow @EmilyWFierce

> Epilepsy device maker NeuroSigma has withdrawn its $50 million IPO, just as brain cancer device player NovoCure seeks $344 million and total artificial heart player SynCardia Systems aims for $28 million in IPOs slated for this week. More

> AdvaMed President and CEO Stephen Ubl is resigning as of Oct. 15; the group is searching for a replacement. He was rumored last week to be joining biopharma industry association PhRMA. More

> Lima has acquired the Japanese rights to the Zimmer Unicompartmental High Flex Knee and the Discovery Elbow System; it had acquired European rights to these earlier this year as part of Zimmer's effort to appease regulators for its combination with Biomet. More

> Thoratec ($THOR) has reported positive 6-month results in its HeartMate 3 CE mark trial for its LVAD circulatory device to support and restore failing hearts. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novo scores a game-changing diabetes approval, reversing an embarrassing rejection. Article | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Roche scores an MS first with a potential blockbuster on its hands. Story

> Roche wins kudos for game-changing atezolizumab cancer data. More

> Westphal's Verastem concedes lead drug flopped in PhII mesothelioma study. Article

Pharma News

@FiercePharma: AKC-funded study IDs similar lymphoma gene types in dogs and people. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Roche is 'well placed' for U.S. pricing tussle, CEO says. Report | Follow @CarlyHFierce

> Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba. Story

> How much more does the U.S. pay for drugs? Up to 10 times more, report says. Article

Animal Health News

> USDA unveils plan to battle avian flu if it re-emerges this fall. Story

> Sanofi rumored to be weighing Merial spinoff. Report

> Investors trounce Aratana on dashed hopes for canine lymphoma drugs. More

> AKC-funded study IDs similar lymphoma gene types in dogs and people. Story

> Rhizen moves into midstage trial of pill to treat canine lymphoma. Article

Biotech IT News

> BioClinica buys pharmacovigilance outfit to continue evolution. Article

> AstraZeneca opens data vault for cancer combo efficacy prediction challenge. Report

> Feds prioritize researcher access to health data in IT action plan. More

> Bayer pairs Genedata Profiler and iRODS to manage omics data analysis. Story

> Venter's HLI strikes low-cost exome sequencing deal to swell data repository. Article

Pharma Marketing News

> International payer report shows U.S. prices almost 10X higher for some meds. Item

> Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick. More

> NEJM: FDA's proposed risk-disclosure guidelines still aren't enough. Story

> Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says. Article

> Not so fast, Hillary. Ad industry will fight with pharma against DTC tax moves. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.